Venus Remedies Closes Cipla Deal With Final Rs 11 Crore Milestone

Venus Remedies announced today that it has received the final milestone payment of Rs 11 crore from Cipla Ltd, completing all commercial milestones outlined in their 2019 agreement.

This marks a key moment for the company’s AMR-focused anti-infective, which Cipla continues to market and distribute across India.

Developed by the Venus Medicine Research Centre (VMRC), the patented product targets multidrug-resistant infections that do not respond well to routine antibiotics.

Over the years, it has been used by more than one million patients and has shown a strong safety record, with no serious drug-related adverse events reported after launch. Its consistent performance has made it an important option in hospitals dealing with hard-to-treat infections and rising antimicrobial resistance.

Also Read: Designing Packaging Systems for Regulatory Compliance and Quality

The company said this milestone reinforces the value of its ongoing work in AMR. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, and CEO, VMRC, said: "The receipt of this final anticipated milestone payment is more than a financial outcome; it is a strong validation of the long-term clinical and commercial relevance of our AMR-focused research. Seeing a home-grown anti-infective reach over a million patients while meeting all performance targets agreed with our partner is deeply encouraging for our teams."

Venus Remedies added that AMR remains a core strategic area. Its pipeline includes differentiated antibacterial candidates such as VRP034 and MET-X, both granted QIDP designation by the US FDA. The company also continues its work in surveillance and stewardship through programs like GASAR and international data-sharing efforts aimed at supporting responsible antibiotic use and improving care for patients with severe infections.